AASLD: Antiviral Likely Too Costly for Initial HCV Tx (CME/CE, with video)
SAN FRANCISCO (MedPage Today) — First-line treatment with the direct-acting antiviral agent telaprevir (Incivek) appeared unlikely to be cost-effective for hepatitis C virus infection in patients with the favorable CC IL28B polymorphism, according to a decision modeling analysis.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com